Corona that is covid-19 spreading in the world .India now a days suffering from second wave of corona .Daily 2 to 3 lakhs new case detected in India.
Precautions:-
1.Social distancing
2.Mask
3.Sanitizer
4.Stay Home
5.Keep Healthy
Test:-
Rapid antigen tests (sometimes known as a rapid diagnostic test – RDT) detect viral proteins (known as antigens). Samples are collected from the nose and throat with a swab. These tests are cheaper than PCR and will offer results more quickly, although they are generally less accurate. These tests perform best when there is more virus circulating in the community and when sampled from an individual during the time they are infectious.
Symptoms:-
Doctors and scientists are learning new things about this virus every day. So far, we know that COVID-19 may not cause any symptoms for some people.
You may carry the virus for 3 days before you develop symptoms.
Some common symptoms that have been specifically linked to COVID-19 include:
Less common symptoms include:
However, individuals with COVID-19 may have some, all, or none of the above symptoms.
Vaccination:-
In india there are many vaccines still vaccination process is lacking to fulfill need of such large population .Indian govt trying to vaccinet whole population as early as possible.
Recently , frace came forward to help india to fight against corona .USA also says to help but india has to fulfill their need its own.
What indian express reported:-
Using a new platform, scientists have developed a Covid-19 vaccine that they say could offer protection against not only existing and future strains of the SARS-CoV-2 coronavirus, but also other coronaviruses. The vaccine is cheap, at $1 a dose, and has shown promising results in early animal testing, the researchers have reported in the journal.
PNAS.
Other Covid-19 vaccines do not appear to be specifically targeting the fusion peptide, to my knowledge,” Zeichner said, in response to an emailed question. “Most vaccines in development target either the entire spike protein, or just the receptor binding domain (RBD).”
While antibodies against the RBD can provide good neutralising activity, there can be mutations in the RBD that decrease somewhat the effectiveness of the antibodies, he said. “I think that making a vaccine that essentially recapitulates almost exactly the antigens made by the virus may be mistaken. The virus has evolved to be able to continue to live even in the presence of an immune response. In a sense, making a vaccine that elicits an immune response against an immunodominant antigen may be ‘falling for’ the ‘tricks’ that the virus has laid out for us,” he said.
